Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects

0507345 - ÚEM 2020 RIV US eng J - Článek v odborném periodiku
Šponer, P. - Kučera, T. - Brtková, J. - Urban, K. - Kočí, Zuzana - Měřička, P. - Bezrouk, A. - Konrádová, Šimona - Filipová, A. - Filip, S.
Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects.
Cell Transplantation. Roč. 27, č. 10 (2018), s. 1459-1468. ISSN 0963-6897. E-ISSN 1555-3892
Institucionální podpora: RVO:68378041
Klíčová slova: mesenchymal stromal cells * scaffold * bone defect * cell therapy
Obor OECD: Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
Impakt faktor: 3.477, rok: 2018
Způsob publikování: Open access
https://journals.sagepub.com/doi/10.1177/0963689718794918

This prospective study sought to evaluate the healing quality of implanted ultraporous beta-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received beta-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received beta-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous beta-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman-Halton modification of the Fischer's exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with beta-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment.
Trvalý link: http://hdl.handle.net/11104/0302805